Research
Hormonal
Chronic stimulation of pancreatic beta-cells by incretin agonists may lead to beta-cell exhaustion, receptor downregulation, and potentially beta-cell failure over the long term.
While generally safe, long-term use of incretin medications may theoretically stress pancreatic beta-cells. Doctors monitor for this, but the long-term human data is still being gathered. It is important to discuss any concerns about long-term safety with your healthcare provider.
LimitedQualifiesLOW confidence
Chronic agonism of pancreatic β-cells may decrease the number of receptors and cause β-cell exhaustion, leading to β-cell failure.
Why this rating
Based on animal studies and theoretical mechanisms; human long-term data is lacking.
Source
Does Incretin Agonism Have Sustainable Efficacy?
Sok‐Ja Janket et al. · Cells · 2024
DOI 10.3390/cells13221842
narrative_reviewCited 6×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Discontinuation of incretin agonists (GLP-1/GIP) leads to significant weight regain (approx. two-thirds of lost weight) within weeks, indicating that current pharmacological efficacy is not sustainable without continuous treatment.Good
- Long-term use of incretin agonists shows attenuated efficacy over time, with weight loss and HbA1c improvements diminishing significantly in the 3rd to 7th year of treatment.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →